BioSpace News Archive

Today, Vyant Bio announced that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference (“Q4 Investor Summit”). The event is being held virtually from November 16-17, 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021.

Casma Therapeutics, Inc., a biotechnology company harnessing the power of autophagy to design innovative new medicines, announced that Chief Executive Officer, Keith Dionne, Ph.D., will present at the upcoming Stifel Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10 a.m. ET.

DiaMedica Therapeutics Inc. today provided a business update and financial results for the quarter ended September 30, 2021. Management will host a conference call Thursday, November 11, 2021, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and third quarter financial results.

Medexus Pharmaceuticals Inc. today announced its financial results and provided a business update for the three-month period ended September 30, 2021.

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update

Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of the Company’s ordinary shares, to be delivered in the form of American Depositary Shares.

MediciNova, Inc. announced that Grazia Ambrosini, PhD, an associate research scientist at Columbia University Vagelos College of Physicians and Surgeons, presented data regarding MN-166 in a uveal melanoma model study at the 10th Annual CURE OM Global Science Meeting held online as a part of the Society for Melanoma Research International Congress on October 28, 2021.

Everest Medicines and Gilead Sciences, Inc. jointly announces that Everest Medicines’ Phase 2b EVER-132-001 study of sacituzumab govitecan met its primary endpoint of overall response rate in metastatic triple-negative breast cancer.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price to the public of $145.00 per share.